Default company panoramic image

BrainDx, LLC

Venture capital to launch FDA 510K approved neurofunctional analyses tool.

  • Stage Concept Only
  • Industry Healthcare Services
  • Location Johns Creek, GA, USA
  • Currency USD

Company Summary

BrainDx has developed a modular system that allows the end user to process brain function on many levels of analysis which can help classify an individual in terms of disorders and identify in three dimensions the locations of brain dysfunctional regions which can be monitored with therapeutic techniques.


  • Default avatar
    David Steven Cantor

    Dr. David Cantor is the CEO of BrainDx. He holds a Bachelors Degree with Distinction in Psychology from the University of Connecticut. He attained Masters and Doctorates in Psychology at the State University of New York at Stony Brook. He also holds a post-doctoral Masters of Science Degree in Psychopharmacology from Farleigh Dickinson University. He a former President of the EEG and Clinical Neuroscience Society.

  • Default avatar
    Leslie Prichep
    R&D Director

    Dr. Leslie Prichep, is R&D Director for BrainDx, LLC. She received her BS and MS degrees from the University of Pittsburgh and a Ph.D. in Experimental Psychopathology from The City University of New York. She has received the Wyeth-Ayerst Award for Distinction in Psychiatry. The author of over a hundred scholarly papers, authored twenty five books, and has many other publications in the field of neuroscience. She is also currently an editor for m

  • Default avatar
    Robert Isenhart

    Robert Isenhart, serving as Chief Technology Officer. A Physics graduate of Ohio State University, he served internationally in the Electronic Intelligence Group of the US Army followed by physics research at the Stanford Nuclear Accelerator at Lawrence Berkeley Laboratories. He has been involved in psychophysiology research in the Department of Psychology at the University of California, Irvine and at New York University Medical School.